argenx is trading 4.59% down at $849.19 ahead of its October 22, 2026 earnings call. The Q3 release is the clearest company-specific event preceding the move, but does not explicitly attribute the pre-market decline to results.

  • Third-quarter product sales were $1.721 billion, up 54% year over year; diluted EPS was $7.80, versus $5.18 a year earlier.
  • Operating expenses were higher; 2026 combined R&D and SG&A expense outlook is approximately $4 billion, including Forte-related costs.